Key Points
- Major shareholder Roger Klein sold 9,000 shares at $10.65 for $95,850, cutting his position by 23.68% to 29,000 shares (valued at about $308,850) as disclosed in an SEC filing.
- Evoke recently reported a quarterly EPS miss (‑$0.62 vs. ‑$0.30 expected), with revenue slightly below estimates and negative profitability metrics, while the company has a small market cap (~$16.7M) despite the stock trading near its 52‑week high.
- Analyst sentiment is weak (average rating "Reduce"), but institutional activity included National Wealth Management Group buying a new ~80,130‑share stake (~5.14% of the company) in Q3.
Evoke Pharma, Inc. (NASDAQ:EVOK - Get Free Report) major shareholder Roger Klein sold 9,000 shares of the business's stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $10.65, for a total value of $95,850.00. Following the completion of the sale, the insider owned 29,000 shares of the company's stock, valued at $308,850. The trade was a 23.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Evoke Pharma Stock Up 0.6%
EVOK opened at $10.69 on Friday. The stock's fifty day moving average is $5.39 and its two-hundred day moving average is $4.41. The company has a market capitalization of $16.68 million, a P/E ratio of -4.18 and a beta of -0.14. Evoke Pharma, Inc. has a 52 week low of $1.94 and a 52 week high of $10.79.
Evoke Pharma (NASDAQ:EVOK - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.32). The firm had revenue of $3.75 million for the quarter, compared to the consensus estimate of $3.80 million. Evoke Pharma had a negative return on equity of 99.48% and a negative net margin of 42.07%.
Analysts Set New Price Targets
EVOK has been the subject of several research reports. Wall Street Zen raised shares of Evoke Pharma from a "sell" rating to a "hold" rating in a research report on Sunday, September 7th. Weiss Ratings reissued a "sell (e+)" rating on shares of Evoke Pharma in a research note on Wednesday, October 8th. Finally, Laidlaw cut Evoke Pharma from a "buy" rating to a "hold" rating in a research report on Thursday. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Evoke Pharma presently has an average rating of "Reduce".
View Our Latest Stock Report on Evoke Pharma
Institutional Investors Weigh In On Evoke Pharma
A hedge fund recently bought a new stake in Evoke Pharma stock. National Wealth Management Group LLC purchased a new position in Evoke Pharma, Inc. (NASDAQ:EVOK - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 80,130 shares of the specialty pharmaceutical company's stock, valued at approximately $398,000. National Wealth Management Group LLC owned about 5.14% of Evoke Pharma at the end of the most recent quarter.
About Evoke Pharma
(
Get Free Report)
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
